China FDA Toughens GMP Enforcement at Foreign Sites
This article was originally published in The Gold Sheet
The China FDA is substantially beefing up inspections of foreign drug manufacturing sites, showing assertiveness and confidence towards China's own GMP standards after a massive domestic campaign to root out quality violators. For companies eyeing the world's second largest pharma market, staying out of trouble will require keeping on top of local regulatory updates, says an industry insider.
Register for our free email digests: